Table 1.
Baseline Patient Demographics and Clinical Characteristics
| Characteristic | Value |
|---|---|
| Age, years, median (range) | 50.5 (29-72) |
| Female, No. (%) | 32 (100) |
| Race, No. (%) | |
| White | 25 (78.1) |
| Black or African American | 7 (21.9) |
| ECOG performance status, No. (%) | |
| 0 | 14 (43.8) |
| 1 | 18 (56.3) |
| Location of metastases | |
| Brain | 3 (9.4) |
| Visceral | 25 (78.1) |
| Nonvisceral | 7 (21.9) |
| LDH level, No. (%) | |
| > ULN | 13 (40.6) |
| ≥ 2× ULN | 5 (15.6) |
| No. of prior therapies for metastatic disease | |
| Median (range) | 2 (0-9) |
| 0, No. (%) | 5 (15.6) |
| 1, No. (%) | 6 (18.8) |
| 2, No. (%) | 6 (18.8) |
| 3, No. (%) | 5 (15.6) |
| 4, No. (%) | 2 (6.3) |
| ≥ 5, No. (%) | 8 (25.0) |
| Previous neoadjuvant or adjuvant therapy, No. (%) | 28 (87.5) |
| Previous chemotherapy exposure, No. (%) | |
| Taxane | 32 (100.0) |
| Anthracycline | 23 (71.9) |
| Capecitabine | 21 (65.6) |
| Platinum | 19 (59.4) |
| Eribulin | 8 (25.0) |
NOTE. Data included a total of 32 patients.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal.